CMP-001 for Relapsed and Refractory Lymphoma

NCT03983668 PHASE1, PHASE2 TERMINATED Results posted

This study is a single-arm, open-label, phase I/II trial designed to find a CMP-001 dose that, in combination with pembrolizumab, has optimal clinical efficacy and acceptable toxicity for patients with relapsed and refractory lymphomas.

Details

Lead sponsor	Umar Farooq
Phase	PHASE1, PHASE2
Status	TERMINATED
Enrolment	14
Start date	Fri Jan 31 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Lymphoma

Interventions

• CMP-001
• Pembrolizumab

Countries

United States